Comparative Pharmacology
Head-to-head clinical analysis: MOXEZA versus ZAGAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXEZA versus ZAGAM.
MOXEZA vs ZAGAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
Sparfloxacin, a fluoroquinolone antibiotic, inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby blocking DNA replication and transcription.
400 mg orally once daily with or without food.
600 mg intravenously once daily or 600 mg orally once daily.
None Documented
None Documented
Terminal half-life: 12 hours; allows once-daily dosing
10-12 hours; prolonged in renal impairment
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Renal: 60-80% unchanged; biliary/fecal: 10-20%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic